About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of ...

In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report), ...

One of the critical reasons is Merck’s plan to launch its subcutaneous version of Keytruda (pembro) earlier than previously anticipated, with a new target date of 2025. This accelerated timeline ...

“Efti+pembro may provide a chemo-free option with similar (close enough) response rates as chemo-containing treatments but a better safety profile,” they said, pointing out that chemo ...

Lenvatinib plus pembrolizumab (len+ pembro) showed improved progression-free survival (PFS) and overall survival (OS) compared to chemotherapy in advanced or recurrent endometrial cancer (aEC) in the ...

Chemoimmunotherapy plus radiotherapy in advanced esophageal squamous-cell carcinoma. Pembro: pembrolizumab, mo: month. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...

“When [PD-1 inhibitors] first came out, we were like ‘everyone gets pembro,’ no matter the PD-L1 expression level because there was literally nothing else,” Harpreet Singh, former FDA division ...

Safety run-in 1 includes pts with RM-HNSCC untreated in the RM setting to receive magrolimab + pembrolizumab (pembro) + platinum (cisplatin or carboplatin) + 5-fluorouracil (FU); safety run-in 2 ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded. [Operator instructions] I would now like to turn the call over to Mr. Peter ...